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Surgical site infections are common, so effective antibiotic concentrations at the sites of infection, i.e., in the
interstitial fluid (ISF), are required. The aim of this study was to evaluate contemporary perioperative
prophylactic dosing of cefazolin by determining plasma and subcutaneous ISF concentrations in patients
undergoing elective/semielective abdominal aortic aneurysm (AAA) open repair surgery. This was a prospective
pharmacokinetic study in a tertiary referral hospital. Cefazolin (2 g) was administered as a 3-min slow bolus
30 min prior to incision in 12 enrolled patients undergoing elective/semielective AAA open repair surgery.
Serial blood, urine, and ISF (via microdialysis) samples were collected and analyzed using a validated liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method. Cardiac output was determined using pulse
waveform contours with Vigileo. The recruited patients had a median (interquartile range) age of 70 (66 to 76)
years and weight of 88 (81 to 95) kg. The median (interquartile range) terminal volume of distribution was 0.14
(0.11 to 0.15) liter/kg, total clearance was 0.05 (0.03 to 0.06) liter/h, and minimum observed unbound concen-
tration was 5.7 (5.4 to 8.1) mg/liter. The penetration of unbound drug from plasma to ISF was 85% (78% to
106%). We found correlations present, albeit weak, between cefazolin clearance and cardiac output (r2  0.11)
and urinary creatinine clearance (r2  0.12). In conclusion, we found that a single 2-g dose of cefazolin
administered 30 min before incision provides plasma and ISF concentrations in excess of the likely MICs for
susceptible pathogens in patients undergoing AAA open repair surgery.
Clean and clean-contaminated surgeries are reported to
have infection rates of 1% and 11%, respectively (1). This is
the second most common type of adverse event occurring in
hospitalized patients (6). The impact of surgical site infection
(SSI) is dependent upon the site and severity of the disease and
the development of further complications. These complica-
tions include bronchopneumonia (8%), renal insufficiency
(5%), and wound infection (3%) as well as myocardial infarc-
tion (3%), stroke (2%), and pulmonary embolism (1%) (14).
In addition to increased morbidity, there are clinical, logistic,
and financial implications, such as antibiotic selection pressure
with evolution of resistance patterns and bed management
issues. Prevention of SSI may therefore represent significant
advantages to the patient and the health care system.
Surgical prophylaxis mandates a comprehensive understand-
ing of pharmacokinetic properties of the selected agent such
that operative perturbations in physiology do not render the
antibiotic redundant. There are a number of confounding is-
sues which should be considered with abdominal aortic aneu-
rysm (AAA) open repair surgery. First, significant hemorrhage
may necessitate volume expansion, transfusion, and vasopres-
sor and/or inotropic support, thereby increasing the clearance
of hydrophilic compounds, including cephalosporin antibiotics
(16). Second, the population is aged (mostly 65 to 75 years
old), with obesity, diabetes, and hypertension, and concomitant
nephropathy and vasculopathy (3, 11, 14) are not uncommon.
The ultimate effect is determined by the balance of a complex
interrelationship of altered physiology and pharmacokinetics,
which has been described in part (16, 17). Finally, the surgery
entails surgically clamping major vessels and the temporary
reduction of renal blood flow and perfusion of other tissues.
The Australian Therapeutic Guidelines recommends the
cephalosporin cefazolin for vascular surgery antibiotic prophy-
laxis (2). It provides excellent Gram-positive and modest
Gram-negative coverage, but consistent with its class, it re-
quires a maximal duration of exposure of the unbound or free
fraction at a level higher than the MIC (fTMIC) for the sus-
pected pathogens. This is otherwise known as time-dependent
killing.
Tissue concentrations of antibiotics are best determined by a
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technique known as microdialysis (4, 7, 16). The relationship
between suboptimal perioperative antibiotic concentration and
surgical site infections has been established for aminoglyco-
sides (21). At this time, there are no studies that describe tissue
concentrations of antibiotics during AAA open repair surgery
or the effect of patient physiology on pharmacokinetics in this
setting.
The main aim of this study was to describe the pharmaco-
kinetics of cefazolin administered intravenously to patients
undergoing elective and semielective AAA open repair sur-
gery, including the kinetics of the drug in interstitial fluid
(ISF). In addition, we aimed to measure the effects of cardiac
output and urinary creatinine clearance (CLCR) on cefazolin
clearance in these patients.
MATERIALS AND METHODS
This prospective observational pharmacokinetic study was conducted exactly
in accordance with a recently published protocol paper (9). It was performed in
the operating theaters and intensive care unit of a 918-bed teaching hospital in
Australia. The study was approved by the Human Research and Ethics Com-
mittee of the Royal Brisbane and Women’s Hospital (2007/187) and the Medical
Research Ethics Committee of The University of Queensland (2008002032).
Patient selection and data collection. Patients scheduled to undergo elective
and semielective AAA open repair surgery with cefazolin as surgical prophylaxis
were eligible for enrolment. Informed consent was obtained from the patient or
the patient’s legally authorized representative.
Cefazolin administration. All participants received 2 g of cefazolin (Cepha-
zolin; DBL, Sydney, Australia) in 10 ml 0.9% sodium chloride as a 3-min slow-
bolus intravenous injection 30 min prior to the first incision of surgery.
Sample collection. Pharmacokinetic sampling occurred in the immediate peri-
operative period. Blood was sampled at 0 min (immediately prior to antibiotic
administration) and then at 3, 10, 30, 60, 90, 180, 300, and 480 min or until at
least the conclusion of surgery. Specimens were centrifuged at 3,000 rpm for 10
min and then frozen at 80°C for subsequent analysis. Urine was collected at
2-hourly intervals during the immediate perioperative period and concluded with
an 8-h postoperative urinary creatinine clearance sample. Urine was stored at
80°C until assay.
In vivo microdialysis. Microdialysis was the technique chosen to measure the
free (or unbound) antibiotic concentration in subcutaneous tissue. Given that the
free antibiotic concentration determines the antibacterial effect (15), this infor-
mation is particularly useful. The principles and details of microdialysis have
been described previously (8). Briefly, microdialysis is based on the sampling of
analytes from the extracellular space by diffusion across a semipermeable mem-
brane. In vivo, this process is accomplished by constantly perfusing the microdi-
alysis probe with a physiological solution at a low flow rate. Once the probe is
implanted in tissue, analytes diffuse across the membrane from the extracellular
fluid into the perfusate and may be sampled and analyzed. In this study, a
microdialysis probe (CMA 60; Microdialysis AB, Stockholm, Sweden) with a
molecular mass cutoff of 20 kDa, an outer diameter of 0.6 mm, and a membrane
length of 30 mm was placed aseptically in the subcutaneous tissue of the upper
arm of each patient. The probe was perfused with cephalothin (10 mg/liter;
internal standard) in 0.9% sodium chloride at a flow rate of 1.6 l/min (7). After
administration of cefazolin, microdialysis samples were collected at 30-min in-
tervals until the conclusion of blood sampling. Samples were stored at 80°C for
assay. The recovery of cefazolin in the microdialysate solution was interpolated
from the loss of internal standard (cephalothin) across the microdialysis mem-
brane into tissue (20), as follows: % cefazolin recovery  100  (Cin  mean
Cout/Cin), where Cin is cephalothin at 10 mg/liter (perfusate) and Cout is the
measured cephalothin concentration in the microdialysate.
Creatinine clearance measurement. Samples for determination of urinary
creatinine clearance were collected over an 8-hour period via an indwelling
urinary catheter. This was performed to determine correlations between renal
function and cefazolin clearance. CLCR was calculated using the formula CLCR
(ml/min)  (urine creatinine concentration [mol/liter]  volume [ml])/(plasma
creatinine concentration [mol/liter]  480 [min]).
Cardiac output measurement. Cardiac output was measured using pulse wave-
form contour analysis with FloTrac/Vigileo (Edwards Lifesciences, Irvine, CA).
Sample analysis. Blood samples were centrifuged at 3,000 rpm for 10 min, and
plasmas were stored at 80°C until assay. The plasma, urine, and microdialysis
samples were analyzed utilizing validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) methodology at the Therapeutics Research Unit,
The University of Queensland.
Plasma samples were prepared by addition of an internal standard (150 l of
10 g/ml cloxacillin in acetonitrile) to 50 l of plasma. After centrifugation, 2 l
of supernatant was injected into the LC-MS/MS instrument to measure total
cefazolin levels. The unbound plasma levels were determined by ultrafiltration of
200 l of plasma (Amicon Ultra [0.5 ml, 10 kDa]) at room temperature to
produce100 l of filtrate, of which 50 l was then assayed as described for total
plasma.
Chromatographic analysis used a Phenomenex Luna C18(2) column (50 mm 
2 mm  5 m) with mobile phases A (0.1% formic acid) and B (95:5:0.1
acetonitrile-water-formic acid). The mobile phase gradient increased (at 300
l/min) from 0% to 90% phase B over 2 min; 90% phase B was maintained for
1.5 min before reverting to 0% phase B for a total run time of 5 min.
Microdialysate samples were assayed for cefazolin and cephalothin by LC-MS/
MS. Five microliters of sample was injected directly using a similar chromato-
graphic method to that for plasma (no internal standard; 10 mM ammonium
acetate substituted for the formic acid in the mobile phase). Urine samples were
also assayed for cefazolin by this method, after appropriate dilution with water.
The antibiotics were detected using an API2000 tandem mass spectrometer
(AB Sciex). The mass spectrometer ion masses were 455 3 323 (cefazolin),
437 3 278 (cloxacillin), and 397 3 152 (cephalothin).
All assay methods were validated according to best practice guidelines, with
precision and accuracy within 15% of the nominal value. The reliability of assay
batches was monitored at three levels with quality control samples.
Pharmacokinetic analysis. The pharmacokinetic values were calculated using
noncompartmental methods. The area under the concentration-time curve from
0 h to the last measurement at the completion of surgery (AUC0-last) was
calculated using the linear trapezoidal rule. The area under the moment curve
from 0 to 8 h (AUMC0–8) was calculated using the linear trapezoidal rule. The
apparent terminal elimination rate constant (z) was determined from log-linear
least-squares regression analysis of concentrations from the final 3 concentra-
tion-time values for each subject. The area under the concentration-time curve
from 0 h to infinity (AUC0-) was calculated using the AUC0-last, the concen-
tration at the last time point (Clast), and z. The area under the moment curve
from 0 h to  (AUMC0-) was calculated using the AUMC0-last, Clast, and z. The
mean residence time (MRT) was calculated as AUMC0-/AUC0-. Total body
clearance (CLtotal) was calculated as dose/AUC0-. The maximum concentration
for the dosing period (Cmax) and the minimum concentration for the dosing
period (Cmin) were observed values; the apparent volume of distribution during
terminal phase (Vz) was calculated as CL/z, and the half-life (t1/2) was calculated
as ln(2)/z.
Statistical analysis. Summary data are presented as medians with interquartile
ranges (IQR), and statistical significance was defined for P values of 0.05.
Correlations between factors were determined using linear regression, with r2
values calculated to determine goodness of fit. Statistical analyses were per-
formed using GraphPad Prism, version 4.03 (GraphPad, San Diego, CA), and
Microsoft Excel (Microsoft Office 2007; Microsoft, Redmond, WA).
RESULTS
Clinical data. Twelve patients were enrolled in the study,
and there were no microdialysis catheter-related complications
or associated morbidity. The clinical and demographic charac-
teristics of the patients are described in Table 1. The median
cross-clamp time of 54 min (IQR, 48 to 66 min) was not
dependent upon the overall duration of surgery, which had an
IQR of 2.6 to 3.2 h. Pharmacokinetic data are presented in
Table 2. Based on the AUC ratios, unbound cefazolin concen-
trations in the plasma closely mirrored unbound concentra-
tions found within the tissues. The median percent protein
binding of cefazolin was 87% (interquartile range, 74 to 90%).
The median plasma albumin concentration was 34 g/liter (in-
terquartile range, 29 to 38 g/liter). The median volume of
intravenous fluids administered perioperatively was 3,180 ml
(interquartile range, 2,589 to 4,036 ml), which correlated with
urinary creatinine clearance (linear regression r2  0.37).
The median perioperative concentration-time profile for ce-
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fazolin fractions during abdominal aortic aneurysm repair sur-
gery when cefazolin was administered 30 min prior to incision
is shown in Fig. 1. The data show that the MIC for methicillin-
sensitive Staphylococcus aureus (MSSA) at our institution, 2
mg/liter, was achieved within the ISF at 30 min, and the peak
of 23.7 mg/liter was relatively delayed, at 2 h. Furthermore,
unbound cefazolin concentrations exceed the MIC in both
blood and ISF for the duration of the operation.
The median 8-h creatinine clearance of 98 ml/min (IQR, 76
to 141 ml/min) is within normal limits and was not dependent
upon the clamp time.
The relationships between systemic cefazolin clearance and
cardiac output and creatinine clearance are shown in Fig. 2 and
3. These data show that there is higher cefazolin clearance with
higher cardiac output (linear regression r2  0.11) and higher
urinary creatinine clearance (linear regression r2  0.12).
DISCUSSION
This is the first study to use microdialysis to investigate ISF
concentrations of cefazolin while simultaneously measuring
plasma pharmacokinetics following a single bolus of 2 g as
prophylaxis during AAA open repair surgery.
We have demonstrated that a 2-g dose administered 30 min
prior to surgical incision will ensure penetration of the ISF of
subcutaneous tissue to levels in excess of the 2-mg/liter MIC90
for MSSA (10). In addition to this, our data show that the
levels are maintained for over 7 h, which is well in excess of the
median duration of the surgery. This nearly complete rapid
penetration of ISF by unbound cefazolin is surprising given the
peripheral vascular disease (PVD) common to these patients.
However, we are unable to compare the ISF time to maximum
(Tmax) and concentration maximum (Cmax) of our population
TABLE 1. Patient demographicsa
Patient no. Age (yr) Wt (kg) Ht (cm) Serum creatinineconcn (mol/liter)
8-h urinary
CLCR (ml/min)
Cardiac output
(liters/h)
Duration of
surgery (h)
Duration of aortic
clamping (h)
1 81 88 178 137 38 4.8 4.6 2.5
2 65 87 176 82 91 5.6 2.5 0.8
3 77 108 183 86 93 5.4 3.0 1.0
4 69 81 173 114 61 4.6 2.0 0.5
5 59 128 181 83 125 5.6 3.9 1.0
6 66 80 180 68 129 5.9 2.6 0.8
7 80 92 180 102 37 1.8 0.8
8 76 80 178 72 68 3.0 1.0
9 62 80 180 90 77 6.4 3.6 0.5
10 76 87 181 91 236 5.0 3.1 1.3
11 70 93 170 91 149 5.4 3.1 2.1
12 66 100 175 75 67 5.9 2.6 0.7
Median 70 88 180 88 98 5.5 3.0 0.9
25th percentile 66 81 176 80 76 5.1 2.6 0.8
75th percentile 76 95 180 94 141 5.8 3.2 1.1
a All patients were male.
TABLE 2. Pharmacokinetic parameters of cefazolin in plasma (total and unbound) and ISF of subcutaneous adipose tissue
Pharmacokinetic parametera
Median value (IQR)
Total plasma Unbound plasma Unbound ISF
Cmax (mg/liter) 404 (289–458) 25.7 (21.6–27.6) 23.7 (17.2–27.1)
Tmax (h) 0.08 (0.08–0.09) 0.08 (0.08–0.09) 2.0 (1.5–3.0)
Cmin (mg/liter) 35.7 (30.4–54.3) 5.7 (5.4–8.1) 6.7 (6.0–6.9)
t1/2 (h) 2.7 (2.4–4.1)
AUMC0-last (mg-h/liter) 53,486 (39,116–72,613) 11,444 (6,650–16,165) 8,675 (7,530–11,942)
AUMC0- (mg-h/liter) 178,899 (103,300–392,810) 535,767 (304,118–641,091) 1,484,890 (485,872–2,255,884)
AUC0-last (mg-h/liter) 452 (420–542) 77.6 (59.0–82.4) 65.6 (51.7–83.5)
AUC0- (mg-h/liter) 670 (518–1,113) 382 (295–420) 2,044 (994–3,857)
MRT (h) 259 (210–347) 1,402 (1,030–1,525) 147 (125–178)
kel (h) 0.26 (0.17–0.28) 0.04 (0.04–0.06) 0.22 (0.18–0.32)
CLtotal (liters/h) 3.01 (1.73–3.94)
Vz (liters) 11.6 (10.2–14.1) 119.3 (115.2–123.3)
Vz (liters/kg) 0.14 (0.11–0.15) 1.31 (1.25–1.40)
fAUCISF tissue /AUCplasma
b 0.15 (0.12–0.19)
fAUCISF tissue /fAUCplasma
b 0.85 (0.78–1.06)
a Cmax, observed maximum concentration; Tmax, time that Cmax was observed; Cmin, observed minimum concentration; t1/2, elimination half-life; AUMC0-last, area
under the moment curve from 0 h to the last measurement at the completion of surgery; AUMC0-, area under the moment curve from 0 h to infinity; AUC0-last, area
under the concentration-time curve from 0 h to the last measurement at the completion of surgery; AUC0-, area under the concentration-time curve from 0 h to infinity;
MRT, mean residence time; kel, elimination rate constant; CLtotal, total clearance; Vz, apparent volume of distribution during terminal phase; fAUCISF tissue, unbound
AUC in interstitial fluid of subcutaneous tissue; AUCplasma, AUC in plasma, obtained using total concentrations; fAUCplasma, AUC in plasma, obtained using unbound
concentrations.
b Calculated using AUC0-last.
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with those of a non-PVD population of patients. The sustained
ISF level may reflect the reduced distribution from the tissues
back to plasma, which is not unexpected due to the high con-
centrations in plasma resulting from high protein binding as
well as the reduced vascular perfusion in the described AAA
population.
The surgical conduct of AAA repair induces some interest-
ing physiological compensatory measures which impact phar-
macokinetics. ISF antibiotic levels were detected prior to the
incision but may not have peaked prior to and/or at the time of
securing of the aneurysm. This is significant, as this phase of
the procedure can be associated with major hemorrhage, which
may then require large volumes of intravenous fluids, with the
former resulting in loss of antibiotic from the circulation and
the latter resulting in dilution of an already reduced concen-
tration. The application of cross clamps impairs supply to the
dependent tissues, and perfusion is reliant on collateral blood
flow.
The impact of application of the infrarenal cross clamp on
renal function may fluctuate with the resultant change in car-
diac output. Gross systemic hypertension or hypotension can
occur, and at a regional level, the clamp can reflect higher
pressures to the kidneys. The subsequent impact of cross-
clamp application on renal function as defined by the 8-h
creatinine clearance is quite unpredictable. However, it is clear
that both increased cardiac output and increased creatinine
clearance are associated with increased cefazolin clearance.
We note that the correlation between creatinine clearance and
cefazolin clearance is weak and postulate that this is due to the
narrow range of creatinine clearances observed in this study.
Notably, the results of our study show a greater-than-expected
cefazolin clearance in the elderly population and are similar to
those for younger morbidly obese patients, who would be ex-
pected to have a significantly higher clearance than the pa-
tients described in the present study (19). The reason for this
is unclear, although it could reflect the high volume of concur-
rent fluid administration (median of 2.5 liters per patient),
which was also found to be correlated with increasing creati-
nine clearance in these patients.
Our data are unique in this respect, as this study represents
the first investigation to correlate drug clearance with cardiac
output and creatinine clearance in the perioperative period.
Although similar findings have been reported for critically ill
septic patients, the correlation with cardiac output suggests an
important consideration in dosing renally eliminated antimi-
crobials in such a setting (12, 13). In this respect, augmented
renal perfusion secondary to hyperdynamic circulation may
promote increased drug elimination (through greater solute
delivery and augmented glomerular filtration) and may help to
explain the increased clearances observed (18). In our cohort,
drug concentrations in ISF and plasma were sufficient through-
out the operative period, although similar pharmacokinetic
studies should be planned for settings where both cardiac out-
put and creatinine clearance are typically elevated, such as
emergent surgery and trauma (5).
Limitations of the study include the small sample size and
the fact that the sample did not include the morbidly and
supermorbidly obese, but given the not insignificant difficulties
associated with this patient group, it is worthy of a separate
study (19).
Conclusions. A single 2-g dose of cefazolin administered 30
min prior to surgical incision provides plasma and ISF concen-
trations in excess of the likely MICs for susceptible pathogens
in patients undergoing AAA open repair surgery. Further stud-
ies like this are required for other surgeries to confirm the
FIG. 1. Median perioperative concentration-time profile for cefa-
zolin during abdominal aortic aneurysm repair surgery. Total cefazolin
plasma concentrations (solid black line), unbound cefazolin plasma
concentrations (solid gray line), and unbound interstitial space fluid
concentrations (dashed black line) are shown for cefazolin adminis-
tered 30 min prior to incision. The dotted gray line represents the
MIC90 (2 mg/liter) for methicillin-susceptible Staphylococcus aureus.
FIG. 2. Relationship between cardiac output and systemic cefazo-
lin clearance. The unbroken line represents the linear line of regres-
sion (r2  0.11).
FIG. 3. Relationship between urinary creatinine clearance and sys-
temic cefazolin clearance. The unbroken line represents the linear line
of regression (r2  0.12).
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appropriateness of standard approaches to prophylactic anti-
microbial dosing in the perioperative setting.
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